TYMS is overexpressed frequently in different kinds of cancers, such as NSCLC, pancreatic, colorectal, and breast cancers, and it has resulted in a poor cancer prognosis and chemotherapy resistance via dysregulating pyrimidine metabolism (TroncarelliFlores et al., 2019; Wu et al., 2019). The gene discussed is TYMS; the disease is breast carcinoma.